House Oversight Committee leaders are delving into allegations against CVS Health that suggest the pharmacy giant may have improperly lobbied lawmakers using confidential patient information. Chairman James Comer (R-Ky.) and Federal Law Enforcement Subcommittee Chairman Clay Higgins (R-La.), have initiated an investigation, evidencing concerns about CVS Health’s ethical boundaries and adherence to privacy laws.
The crux of the issue revolves around Louisiana's proposed House Bill 358, which seeks to prevent dual operations of Pharmacy Benefit Managers (PBMs) and individual pharmacies. As per a letter obtained by the House Committee on Oversight and Government Reform, Comer and Higgins underscored how CVS used a text message campaign to potentially sway individuals to oppose the bill. The use of personal information for such purposes is concerning and raises ethical and potential legal issues, according to the lawmakers.
In their letter to CVS Health President and CEO David Joyner, Comer and Higgins have requested a comprehensive trail of documents and communication that could shed light on the alleged use of confidential patient information from January 1, 2020, onward. The implications of the investigation are wide-reaching, as CVS Health operates numerous subsidiaries and could, theoretically, misuse confidential patient data to undermine similar legislative efforts in other states or even at the federal level.
According to the representatives, the Health Insurance Portability and Accountability Act (HIPAA) does not condone the use of protected patient information for political advocacy or lobbying without explicit authorization—a line CVS seems to have crossed. "The HIPAA Privacy Rule does not include political advocacy or lobbying among the list of 'uses and disclosures that may be made of patient information without an individual's authorization,'" the lawmakers noted in the letter. This controversy puts the spotlight on a major health care provider, questioning its commitment to protecting sensitive customer data from being employed for unsanctioned political maneuvering, as noted by the House Committee on Oversight and Government Reform.
This inquiry builds on an ongoing effort by the House Committee to pull back the veil on PBMs’ operations and promote transparency for American consumers. With a focal point on CVS Health, the Committee is confronting issues central to privacy, competition, and health care costs. The overarching goal of the Committee's actions remains clear: to defend individuals from having their personal health information mishandled in a manner that contravenes their expectations of privacy and federal regulations.
